Drugs / SIBP-A19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06990464 | Jun 2025 → Dec 2028 expected | cancer | Shanghai Institute Of Biological Products | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-02-05 | China National Biotec Group Company Limited | Regulatory 新年开新局丨1类创新型抗体偶联药物获批临床 cnbg.com.cn ↗
1月24日，中国生物上海生物制品研究所自主研发的1类创新型抗体偶联药物（ADC）SIBP-A19获得国家药品监督管理局临床试验批准通知书。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-02-05 | China National Biotec Group Company Limited | 新年开新局丨1类创新型抗体偶联药物获批临床 cnbg.com.cn ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIBP-A19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06990464 ↗ |
| Route | Intravenous | “Intravenous infusion administration” NCT06990464 ↗ |